On the public citation graph
More Alzheimer’s drugs head for FDA review: what scientists are watching
0 signed · 22 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2021.14861openalex-snapshot
A Middle Ground for Accelerated Drug Approval—Lessons From Aducanumab
inferredcites →https://doi.org/10.1001/jamainternmed.2021.4607openalex-snapshot
Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective
inferredcites →https://doi.org/10.1056/nejmc2111960openalex-snapshot
An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease
inferredcites →https://doi.org/10.1056/nejmoa2100708openalex-snapshot
Donanemab in Early Alzheimer’s Disease
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4000799openalex-extracted
Sequential versus Concurrent Final Phase Product Development: Approval Uncertainty, Time-Sensitive Consumers, and Asymmetric Competition
inferred← citeshttps://doi.org/10.2139/ssrn.4074460openalex-extracted
Process Choice Under Asymmetric Competition with Exogenous and Endogenous Product Success Probabilities
inferred← citeshttps://doi.org/10.1002/pro.5008openalex-snapshot
Native ion mobility‐mass spectrometry reveals the binding mechanisms of anti‐amyloid therapeutic antibodies
inferred← citeshttps://doi.org/10.1007/978-3-031-31570-1_19openalex-snapshot
Driving Forces of Alzheimer’s Research Directions
inferred← citeshttps://doi.org/10.1007/978-3-031-61992-2_4openalex-snapshot
Drug Discovery in CNS: Finding a Target for What?
inferred← citeshttps://doi.org/10.1007/978-3-662-72210-7_19openalex-snapshot
Treibende Kräfte bei der Ausrichtung der Alzheimer-Forschung
inferred← citeshttps://doi.org/10.1007/s00210-022-02250-2openalex-snapshot
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
inferred← citeshttps://doi.org/10.1007/s40259-022-00550-wopenalex-snapshot
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
inferred← citeshttps://doi.org/10.1016/j.apmr.2023.09.013openalex-snapshot
The Role of Rehabilitation for Early-Stage Alzheimer's Disease and Related Dementias: Practice and Priorities
inferred← citeshttps://doi.org/10.1016/j.ijpe.2024.109315openalex-snapshot
Process choice under asymmetric competition with exogenous and endogenous product success probabilities
inferred← citeshttps://doi.org/10.1016/j.mtbio.2025.101771openalex-snapshot
Molecular architectures of glycosylated dendronized bottle brushes in action: Biocompatibility and anti-amyloidogenic activity of pseudo-glycodendrimers
inferred← citeshttps://doi.org/10.1039/d2sc05418copenalex-snapshot
Deconvoluting binding sites in amyloid nanofibrils using time-resolved spectroscopy
inferred← citeshttps://doi.org/10.1080/09603123.2022.2163988openalex-snapshot
In vitro and in silico cholinesterase inhibitory and antioxidant effects of essential oils and extracts of two new Salvia fruticosa mill. cultivars (Turgut and Uysal) and GC-MS analysis of the essential oils
inferred← citeshttps://doi.org/10.1186/s13024-023-00618-3openalex-snapshot
Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer’s disease: an updated overview of nonpharmacological therapies
inferred← citeshttps://doi.org/10.12788/jfp.0397openalex-snapshot
Patients asking about APOE gene test results? Here’s what to tell them
inferred← citeshttps://doi.org/10.3389/fphar.2022.900610openalex-snapshot
Lipid-based nanoparticles and RNA as innovative neuro-therapeutics
inferred← citeshttps://doi.org/10.3390/biom12070996openalex-snapshot
Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease
inferred← citeshttps://doi.org/10.3390/cells12030420openalex-snapshot
The Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer’s Disease
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.